W
William H. Schultz
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 49
Citations - 2665
William H. Schultz is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Sickle cell anemia & Stroke. The author has an hindex of 25, co-authored 48 publications receiving 2443 citations. Previous affiliations of William H. Schultz include St. Jude Children's Research Hospital & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia - TCD with Transfusions Changing to Hydroxyurea (TWiTCH): A multicentre, open-label, phase 3, non-inferiority trial
Russell E. Ware,Barry R. Davis,William H. Schultz,R. Clark Brown,Banu Aygun,Sharada A. Sarnaik,Isaac Odame,Beng Fuh,Alex George,William Owen,Lori Luchtman-Jones,Zora R. Rogers,Lee Hilliard,Cynthia Gauger,Connie M. Piccone,Margaret T. Lee,Janet L. Kwiatkowski,Sherron M. Jackson,Scott T. Miller,Carla W. Roberts,Matthew M. Heeney,Theodosia A. Kalfa,Stephen C. Nelson,Hamayun Imran,Kerri Nottage,Ofelia A. Alvarez,Melissa Rhodes,Alexis A. Thompson,Jennifer A. Rothman,Kathleen J. Helton,Donna R. Roberts,Jamie L. Coleman,Melanie J. Bonner,Abdullah Kutlar,Niren Patel,John C. Wood,Linda B. Piller,Peng Wei,Judy Luden,Nicole A. Mortier,Susan E. Stuber,Naomi L.C. Luban,Alan R. Cohen,Sara L. Pressel,Robert J. Adams +44 more
TL;DR: High-risk children with sickle cell anaemia and abnormal TCD velocities who have received at least 1 year of transfusions, and have no MRA-defined severe vasculopathy, hydroxycarbamide treatment can substitute for chronic transfusions to maintain TCD velocity and help to prevent primary stroke.
Journal ArticleDOI
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease
Sherri A. Zimmerman,William H. Schultz,Jacqueline S. Davis,Chrisley V. Pickens,Nicole A. Mortier,Thad A. Howard,Russell E. Ware +6 more
TL;DR: Hydroxyurea therapy is well tolerated by pediatric patients with SCD and has sustained hematologic efficacy with apparent long-term safety, and HbF induction has been sustained for up to 8 years without adverse effects on growth or increased numbers of acquired DNA mutations.
Journal ArticleDOI
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia
TL;DR: Preliminary data indicate that hydroxyurea can significantly decrease elevated TCD flow velocities, often into the normal range, and a multicenter trial is warranted to determine the efficacy of hydroxyUREa for the management of increased TCD values, and ultimately for primary stroke prevention in children with SCA.
Journal ArticleDOI
Hydroxyurea as an Alternative to Blood Transfusions for the Prevention of Recurrent Stroke in Children With Sickle Cell Disease
TL;DR: Preliminary data suggest some children with SCD and stroke may discontinue chronic transfusions and use HU therapy to prevent stroke recurrence and modifications in HU Therapy to raise HbF more rapidly might increase protection against strokes recurrence.
Journal ArticleDOI
Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy
Russell E. Ware,Sherri A. Zimmerman,Pamela B. Sylvestre,Nicole A. Mortier,Jacqueline S. Davis,William R. Treem,William H. Schultz +6 more
TL;DR: For children with SCA and stroke, hydroxyurea effectively prevents secondary stroke and serial phlebotomy leads to complete resolution of transfusional iron overload.